ProPhase Labs Inc (PRPH) - Net Assets
Based on the latest financial reports, ProPhase Labs Inc (PRPH) has net assets worth $-3.11 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($57.41 Million) and total liabilities ($60.52 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PRPH strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.11 Million |
| % of Total Assets | -5.42% |
| Annual Growth Rate | 3.77% |
| 5-Year Change | -94.02% |
| 10-Year Change | -41.16% |
| Growth Volatility | 624.33 |
ProPhase Labs Inc - Net Assets Trend (1996–2025)
This chart illustrates how ProPhase Labs Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see PRPH stock market capitalisation.
Annual Net Assets for ProPhase Labs Inc (1996–2025)
The table below shows the annual net assets of ProPhase Labs Inc from 1996 to 2025. Also explore net asset momentum of ProPhase Labs Inc to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $3.51 Million | -52.29% |
| 2024-12-31 | $7.35 Million | -85.11% |
| 2023-12-31 | $49.38 Million | -22.39% |
| 2022-12-31 | $63.63 Million | +8.53% |
| 2021-12-31 | $58.63 Million | +455.40% |
| 2020-12-31 | $10.56 Million | -6.01% |
| 2019-12-31 | $11.23 Million | -31.95% |
| 2018-12-31 | $16.50 Million | -50.12% |
| 2017-12-31 | $33.09 Million | +455.00% |
| 2016-12-31 | $5.96 Million | -32.47% |
| 2015-12-31 | $8.83 Million | -17.61% |
| 2014-12-31 | $10.72 Million | -14.93% |
| 2013-12-31 | $12.60 Million | +10.00% |
| 2012-12-31 | $11.45 Million | +2.00% |
| 2011-12-31 | $11.23 Million | -16.60% |
| 2010-12-31 | $13.46 Million | -4.26% |
| 2009-12-31 | $14.06 Million | -20.90% |
| 2008-12-31 | $17.77 Million | -23.71% |
| 2007-12-31 | $23.30 Million | -8.97% |
| 2006-12-31 | $25.59 Million | +0.86% |
| 2005-12-31 | $25.37 Million | +15.56% |
| 2004-12-31 | $21.96 Million | +5.63% |
| 2003-12-31 | $20.79 Million | +12.83% |
| 2002-12-31 | $18.42 Million | -13.10% |
| 2001-12-31 | $21.20 Million | -0.04% |
| 2000-12-31 | $21.21 Million | -19.05% |
| 1999-12-31 | $26.20 Million | -41.26% |
| 1998-12-31 | $44.60 Million | +6.95% |
| 1997-12-31 | $41.70 Million | +3375.00% |
| 1996-12-31 | $1.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ProPhase Labs Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7033600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.00K | 0.11% |
| Other Comprehensive Income | $-198.00K | -5.64% |
| Other Components | $76.84 Million | 2190.36% |
| Total Equity | $3.51 Million | 100.00% |
ProPhase Labs Inc Competitors by Market Cap
The table below lists competitors of ProPhase Labs Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Aquila Energy Efficiency Trust PLC
LSE:AEET
|
$238.80K |
|
Dianomi PLC
LSE:DNM
|
$239.31K |
|
Veg of Lund AB
ST:VOLAB
|
$239.80K |
|
RT Minerals Corp
V:RTM
|
$240.09K |
|
First Merchants Corporation Depository Shares
NASDAQ:FRMEP
|
$238.22K |
|
Murray & Roberts Holdings Ltd
JSE:MUR
|
$238.01K |
|
TARGA EXPLORATION CORP.
F:V6Y
|
$237.86K |
|
First Eagle Alternative Capital BDC Inc
NYSE:FCRX
|
$237.73K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ProPhase Labs Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,353,000 to 3,508,000, a change of -3,845,000 (-52.3%).
- Net loss of 14,743,000 reduced equity.
- New share issuances of 3,558,000 increased equity.
- Other factors increased equity by 7,340,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-14.74 Million | -420.27% |
| Share Issuances | $3.56 Million | +101.43% |
| Other Changes | $7.34 Million | +209.24% |
| Total Change | $- | -52.29% |
Book Value vs Market Value Analysis
This analysis compares ProPhase Labs Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.04x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | $0.95 | $0.02 | x |
| 1997-12-31 | $28.40 | $0.02 | x |
| 1998-12-31 | $29.84 | $0.02 | x |
| 1999-12-31 | $23.08 | $0.02 | x |
| 2000-12-31 | $19.88 | $0.02 | x |
| 2001-12-31 | $19.72 | $0.02 | x |
| 2002-12-31 | $16.91 | $0.02 | x |
| 2003-12-31 | $13.94 | $0.02 | x |
| 2004-12-31 | $15.16 | $0.02 | x |
| 2005-12-31 | $19.04 | $0.02 | x |
| 2006-12-31 | $20.85 | $0.02 | x |
| 2007-12-31 | $18.26 | $0.02 | x |
| 2008-12-31 | $13.80 | $0.02 | x |
| 2009-12-31 | $10.85 | $0.02 | x |
| 2010-12-31 | $9.42 | $0.02 | x |
| 2011-12-31 | $7.58 | $0.02 | x |
| 2012-12-31 | $7.71 | $0.02 | x |
| 2013-12-31 | $7.74 | $0.02 | x |
| 2014-12-31 | $6.39 | $0.02 | x |
| 2015-12-31 | $0.54 | $0.02 | x |
| 2016-12-31 | $3.49 | $0.02 | x |
| 2017-12-31 | $20.29 | $0.02 | x |
| 2018-12-31 | $14.48 | $0.02 | x |
| 2019-12-31 | $9.71 | $0.02 | x |
| 2020-12-31 | $9.10 | $0.02 | x |
| 2021-12-31 | $31.88 | $0.02 | x |
| 2022-12-31 | $34.12 | $0.02 | x |
| 2023-12-31 | $28.70 | $0.02 | x |
| 2024-12-31 | $3.85 | $0.02 | x |
| 2025-12-31 | $0.41 | $0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ProPhase Labs Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -420.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -339.31%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 17.07x
- Recent ROE (-420.27%) is below the historical average (-47.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | -58.33% | -87.50% | 0.57x | 1.17x | $-820.00K |
| 1997 | 50.36% | 29.91% | 1.41x | 1.19x | $16.83 Million |
| 1998 | 15.25% | 18.68% | 0.75x | 1.09x | $2.34 Million |
| 1999 | -16.03% | -16.94% | 0.74x | 1.27x | $-6.82 Million |
| 2000 | -24.78% | -26.84% | 0.74x | 1.24x | $-7.29 Million |
| 2001 | 1.02% | 0.88% | 1.00x | 1.17x | $-1.90 Million |
| 2002 | -35.04% | -21.94% | 1.18x | 1.35x | $-8.30 Million |
| 2003 | 3.25% | 1.63% | 1.58x | 1.26x | $-1.40 Million |
| 2004 | 2.07% | 1.03% | 1.39x | 1.44x | $-1.74 Million |
| 2005 | 12.70% | 5.99% | 1.49x | 1.42x | $684.72K |
| 2006 | -6.85% | -4.15% | 1.21x | 1.36x | $-4.30 Million |
| 2007 | -10.58% | -6.23% | 1.18x | 1.43x | $-4.78 Million |
| 2008 | -31.14% | -26.99% | 0.84x | 1.37x | $-7.31 Million |
| 2009 | -27.33% | -19.39% | 1.00x | 1.41x | $-5.25 Million |
| 2010 | -26.01% | -24.14% | 0.67x | 1.61x | $-4.85 Million |
| 2011 | -24.14% | -15.53% | 0.91x | 1.70x | $-3.83 Million |
| 2012 | -9.53% | -4.87% | 1.34x | 1.45x | $-2.24 Million |
| 2013 | 3.22% | 1.62% | 1.44x | 1.38x | $-854.60K |
| 2014 | -73.11% | -35.50% | 1.37x | 1.50x | $-8.91 Million |
| 2015 | -40.77% | -17.47% | 1.39x | 1.68x | $-4.48 Million |
| 2016 | -48.10% | -13.65% | 1.64x | 2.15x | $-3.46 Million |
| 2017 | 131.35% | 423.95% | 0.29x | 1.07x | $38.65 Million |
| 2018 | -10.54% | -13.26% | 0.63x | 1.26x | $-3.39 Million |
| 2019 | -28.01% | -31.86% | 0.80x | 1.09x | $-4.27 Million |
| 2020 | -20.13% | -14.64% | 0.46x | 2.98x | $-3.18 Million |
| 2021 | 10.70% | 7.94% | 0.89x | 1.52x | $410.20K |
| 2022 | 29.02% | 15.05% | 1.40x | 1.38x | $12.10 Million |
| 2023 | -33.98% | -37.81% | 0.48x | 1.86x | $-21.72 Million |
| 2024 | -725.74% | -788.24% | 0.11x | 8.60x | $-54.10 Million |
| 2025 | -420.27% | -339.31% | 0.07x | 17.07x | $-15.09 Million |
Industry Comparison
This section compares ProPhase Labs Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $639,611,180
- Average return on equity (ROE) among peers: -114.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ProPhase Labs Inc (PRPH) | $-3.11 Million | -58.33% | N/A | $238.57K |
| Agilent Technologies Inc (A) | $5.29 Billion | 10.38% | 1.04x | $43.76 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Million | -2.92% | 0.87x | $10.44 Million |
| Applied DNA Sciences Inc (APDN) | $12.91 Million | -64.90% | 0.72x | $3.99 Million |
| Biodesix Inc (BDSX) | $19.73 Million | -218.78% | 2.86x | $285.72 Million |
| bioAffinity Technologies, Inc. (BIAF) | $7.28 Million | -204.87% | 0.51x | $17.63 Million |
| Biocept Inc. (BIOCQ) | $11.20 Million | -224.43% | 0.58x | $262.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $30.47 Million | -271.32% | 5.29x | $4.66 Billion |
| Burning Rock Biotech Ltd (BNR) | $1.16 Billion | -83.85% | 0.37x | $129.51 Million |
| CareDx Inc (CDNA) | $-150.67 Million | 0.00% | 0.00x | $2.59 Billion |
| Check Cap Ltd (CHEK) | $16.38 Million | -84.54% | 0.20x | $9.42 Million |
About ProPhase Labs Inc
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart … Read more